Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Ayla

Fearne Cotton drops new Nobody's Child range with summer dresses starting at £35

The collection is said to be inspired by her favourite beauty spot

Liverpool Echo · Jul 7, 2023

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Benzinga · Jul 27, 2022

Why Is Ayala Pharmaceuticals Trading Higher By Around 130%? 45 Stocks Moving In Tuesday's Mid-Day Session

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) jumped 130% to $2.0001 after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Benzinga · Jul 26, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Walmart is Trading Lower By More Than 9%: Here Are 25 Stocks Moving Premarket

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) rose 64.4% to $1.43 in pre-market trading. Ayala Pharmaceuticals filed request for withdrawal of registration statement on form S-1.

Benzinga · Jul 26, 2022

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

Ayala Pharmaceuticals Inc (NASDAQ:AYALA) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the…

Benzinga · Jul 6, 2022

Ayala Reveals Positive Results From Phase 2/3 Desmoid Tumors Study

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) announced positive interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical trial evaluating AL102 in desmoid tumors.

Benzinga · Jul 5, 2022

Ayala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage Study

Ayala Pharmaceuticals Inc (NASDAQ:AYLA) announced interim results from Part A of the ongoing RINGSIDE Phase 2/3 trial evaluating AL102 in desmoid tumors. MRI scans showed decreases in tumor size in most of the 13 patients who had reached the 16-week point. One patient reached an unconfirmed partial response at week 16. AL102 was…

Benzinga · Jul 5, 2022

Read news from The Economist, FT, and more,
with one subscription

What people are saying about Newcastle's newest restaurants and bars such as 3SIXTY, Jollibee and Cafe Andaluz

We take a look at what reviewers are saying about some of Newcastle's newest bars and restaurants

Chronicle Live · Jun 18, 2022

Ayala Pharmaceuticals: Q1 Earnings Insights

Ayala Pharmaceuticals (NASDAQ:AYLA) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga · May 16, 2022

Ayala Pharmaceuticals's Return On Capital Employed Overview

Benzinga Pro data, Ayala Pharmaceuticals (NASDAQ:AYLA) reported Q4 sales of $1.15 million. Earnings fell to a loss of $10.05 million, resulting in a 2.58% decrease from last quarter.

Benzinga · Mar 29, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.